PATENT CLAIM ANALYSIS

Application Number: 15743622
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["514", "029000"]

Abstract:
The present invention provides a therapeutic agent for myotonic dystrophy which inhibits aberrant splicing responsible for myotonic dystrophy, resulting in an increase in a normally spliced product and thus improvement in a symptom of myotonic dystrophy, and is highly safe for use in long-term administration. The therapeutic agent for myotonic dystrophy comprises, as an active ingredient, at least one compound selected from the group consisting of erythromycin, clarithromycin and azithromycin, a pharmaceutically acceptable salt or hydrate thereof, or a prodrug thereof.

Claim (Index 9):
A method for inhibiting aberrant splicing caused by abnormal expansion in a dystrophia myotonica protein kinase (DMPK) gene, the method comprising:\n selecting a mammal to receive an agent that inhibits aberrant splicing caused by abnormal expansion in a dystrophia myotonica protein kinase (DMPK) gene; and administering, to said mammal, an effective amount of at least one compound selected from the group consisting of erythromycin, clarithromycin and azithromycin, a pharmaceutically acceptable salt or solvate thereof, or a prodrug thereof.

Metadata:
- Claim Count in Document: 3.0
- Percentile: 86.0
- Lexical Diversity: 1.55172
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14431115', '10591883', '14297137', '14352717', '12918696']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7182043983191988
- 35 USC 102 Novelty (BERT): 0.5067129630257102
- Combined Prediction Score: 0.69705525478985
- Mean Citation Score: 238.43940200000003
- Max Citation Score: 268.1818
- Similarity Product: 212.3069684269905

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test